Actively Recruiting
Evaluating Low Dose Nivolumab Infusion in Adults with HIV on Antiretroviral Therapy to Reduce the Latent HIV Reservoir
Led by University of Melbourne · Updated on 2025-12-22
42
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether a single dose of Nivolumab can reduce the latent HIV reservoir in adults living with HIV who are on antiretroviral therapy ART. The latent HIV reservoir consists of immune cells infected with HIV but not actively producing virus, which is why continuous ART is necessary. This study aims to better understand if low-dose Nivolumab can affect this reservoir and potentially impact HIV treatment. The study has two parts. Part 1 is an open-label dose escalation phase where participants receive a single intravenous dose of Nivolumab at varying levels 0.1, 0.3, or 1.0 mgkg with follow-up for up to 6 months. Part 2 is a double-blind, randomized, placebo-controlled trial where participants receive either a fixed single dose of 1.0 mgkg Nivolumab or placebo intravenously, followed by up to 6 months of treatment interruption before restarting ART. The total study duration is about 6.3 months for Part 1 and approximately 8 months for Part 2. Participants will undergo screening, treatment administration, and follow-up visits that include monitoring for adverse events and measuring immune responses and viral levels. Assessments include blood and lymph node tests to track Nivolumabs effects on immune cells, HIV RNA levels, and viral rebound during treatment interruption. Safety and immunogenicity are closely observed throughout the study. The primary outcomes focus on treatment-emergent adverse events, while secondary outcomes assess immune markers and viral activity over several time points.
CONDITIONS
Brief Title
Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy
Research Team
J
Jennifer Audsley, BAppSC(Hons), PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here